Biohaven Pharmaceutical Holding Co Ltd
Biohaven Pharmaceutical — Investor Presentation (October 2019)
67 slides from Biohaven Pharmaceutical's investor presentation, Oct 3, 2019
Slide 1: Biohaven Investor Presentation
NEURO INNOVATION BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved. Biohaven Investor Presentation October 3, 2019
Slide 2: Disclaimer
Disclaimer SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 2 This presentation contains forward - looking statements within the meaning of “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including: statements about our plans to
Slide 3: Biohaven's Neuroinnovation Portfolio
Biohaven’s Neuroinnovation Portfolio SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 3 Late Stage Development Pipeline Pre - Clinical CGRP antagonism RIMEGEPANT Phase 3 Zydis ® ODT Acute Migraine COMPLETED RIMEGEPANT Phase 3 Acute Migraine COMPLETED RIMEGEPANT P
Slide 4: Aspire to Achieve
Aspire to Achieve • 3 Marketed drugs by 2021 • Grow while maintaining lean, efficient and high performing culture meeting patient needs growing value SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 4 Goal:
Slide 5: CGRP Platform: Therapies for Migraine
CGRP PLATFORM Therapies for Migraine
Slide 6: Rimegepant FDA Mid Cycle Communication Update
SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 6 Rimegepant FDA Mid Cycle Communication Update (October 1, 2019): Rimegepant ODT and Tablet NDAs At this time, there are no major safety concerns identified; we do not anticipate the need for a REMS at this time.
Slide 7: Multiple Formulations to Meet Patient Needs from Acute to Preventive
Multiple Formulations With the Potential to Meet Patient Needs from Acute to Preventive Treatment of Migraine SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 7 NO JECTION™ CGRP Drug Delivery Platform 1. Exclusive World - Wide License with Catalent for use of Zyd
Slide 8: Biohaven Strategy: Oral Agents with Dual-Therapy Action
Biohaven Strategy: Advance Oral Agents with Potential Dual - Therapy Action (Acute and Preventive Tx) ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR PREVENTIVE TREATMENT • Indicated based on headache frequency & headache related impairment, including: • Chronic Migraine (CM)
Slide 9: Rimegepant Value Proposition: One and Done
Rimegepant Value Proposition: “One and Done” SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 9 Rapid Pain Relief Zydis ® ODT Durable Benefits through 2 days Placebo - like Tolerability
Slide 10: Rimegepant Clinical Trials Published in NEJM and The Lancet
Rimegepant Clinical Trials Published in NEJM and The Lancet Articles SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 10 Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised , phase 3, dou
Slide 11: Rimegepant Zydis ODT Phase 3 Study in Acute Treatment of Migraine
Rimegepant 75 mg Zydis ® ODT Phase 3 Results: Study 303 in the Acute Treatment of Migraine
Slide 12: Rimegepant ODT Broad Spectrum of Efficacy (Study 303)
Rimegepant ODT Broad Spectrum of Efficacy (Study 303) Superiority Over Placebo on 21 Consecutive, Hierarchically - Tested Endpoints SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 12 Favors Placebo Favors Rimegepant 1º Pain freedom, 2 hrs 21.2 10.9 10.4 (6.5, 14
Slide 13: Efficacy Highlights: Early and Sustained Effects with a Single Dose
RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 13 Efficacy Highlights: Rimegepant Zydis ® ODT Shows Early and Sustained Effects with a Single Dose Pain Relief *60 min *90 min *2 hr *24 hr *48 hr Sustained Sustai
Slide 14: Pain Relief: Early Separation From Placebo
RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT Pain Relief: Rimegepant Zydis ® ODT Shows Early Separation From Placebo Beginning within 15 Minutes and is Statistically Significant by 60 Minutes SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 1. Pain Relief is
Slide 15: Rescue Medication Use
RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT Rescue Medication Use : Rimegepant Treated Patients Had Lower Use of Rescue Meds and Delayed Time to Use *Data are Kaplan - Meier estimates of Rescue Medicine Use; subjects were censored (not included) at the time of taking rescue medi cation, and th
Slide 16: Safety Profile: Rimegepant 75 mg ODT
RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT Safety Profile: Rimegepant 75 mg ODT was Well Tolerated and Low Rates of AEs SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 16 • The most common AEs were nausea and urinary tract infection (≤1.6%) • There were n
Slide 17: Pooled Liver Function Test Profile
RIMEGEPANT (BHV - 3000) PHASE 3 – 301 , 302 (75 MG TABLET) & 303 (75 MG ZYDIS ® ODT) Pooled Liver Function Test (LFT) Profile: Rimegepant Liver Safety was Similar to Placebo Across Studies ALT or AST Rimegepant N=1771 Placebo N=1785 > ULN 2 48 (2.7%) 52 (2.9%) > 3x ULN 2 (0.1%) 2 (0.1%) > 5x ULN 1 (
Slide 18: Summary: Rimegepant 75 mg ODT Profile
RIMEGEPANT PHASE 3 – STUDY 303, 75 MG ZYDIS ® ODT Summary : Rimegepant 75 mg ODT – Profile of Rapid and Sustained Effect in the Acute Treatment of Migraine SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 18 • Rapid onset of pain relief with single dose • Numeric
Slide 19: Rimegepant Long Term Safety: Study 201 Interim Analysis
RIMEGEPANT LONG TERM SAFETY – STUDY 201, INTERIM ANALYSIS 13JUN2 019 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 19 • 111,573 doses of rimegepant 75 mg administered across 1,798 patients with migraine • Median number of days in study 278 • <3% of subjects di
Slide 20: Long Term Safety Study: Fixed-Dosing Cohort LFT Results
RIMEGEPANT (BHV - 3000) LONG TERM SAFETY STUDY – STUDY 201, INTER IM ANALYSIS 13JUN2019 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 20 • Subjects in the 12 - week scheduled every other day plus as needed dosing on alternate days (QOD+PRN) cohort (n=286) were
Slide 21: Study 201 On-Treatment Central Labs LFT Results
RIMEGEPANT LONG TERM SAFETY – STUDY 201, INTERIM ANALYSIS 13JUN2 019, ON - TREATMENT CENTRAL LABS Fixed - Dosing (QOD+PRN) Study 201 Cohort LFT Results ALT or AST Rimegepant N=286 > 3x ULN 0 > 5x ULN 0 > 10x ULN 0 > 20x ULN 0 Total Bilirubin > 2x ULN 0 Alkaline Phosphatase > 2x ULN 0 LFT Results fro
Slide 22: Reduction in Moderate-Severe Migraine Days in Fixed-Dosing Cohort
• 48.4% of subjects in the fixed - dosing QOD+PRN cohort experienced ≥50% reduction from baseline during month 3 in the frequency of monthly migraine days with moderate - to - severe pain intensity RIMEGEPANT LONG TERM SAFETY STUDY – STUDY 201 Rimegepant Fixed - Dosing Cohort Preliminarily Shows Red
Slide 23: Improvement in Migraine-Specific Disability (MIDAS)
33.0 20.7 19.1 17.8 17.2 15 20 25 30 35 baseline 12 24 36 52 Mean MIDAS Total Score N=1631 N=1211 N=1085 N=917 N=1789 P<.0001 versus baseline – all time points Time (weeks) *Lower score reflects improvement Improvement in Migraine - Specific Disability after Dosing with Rimegepant 75 mg up to Once D
Slide 24: Rimegepant Reduces Lost Productivity Time
TIME (weeks) Absenteeism Days of missed work, school, household, social or leisure activities due to migraine P <.0001 vs baseline for all timepoints 17.8 10.7 9.6 8.9 8.9 16.2 10 9.4 8.7 8.4 5 8 11 14 17 20 baseline 12 24 36 52 ABSENTEEISM PRESENTEEISM Presenteeism Days when migraine interfered wit
Slide 25: Improved Health Related Quality of Life Outcomes
Treatment with Rimegepant 75 mg up to Once Daily Improves Outcomes on Health Related Quality of Life ( HRQoL ) 14.5 15.4 17.4 17.6 11.5 12.8 13.7 14.4 15.4 15.8 17 .0 17.2 0 2 4 6 8 10 12 14 16 18 20 0 Weeks 12 Weeks 24 Weeks 36 Weeks 52 Weeks Restrictive Role Preventative Role Emotional Function P<
Slide 26: Prevention Strategy: Treatment Paradigm as a Continuum
Prevention Strategy: Redefine the Treatment Paradigm as a Continuum SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 26 • Rimegepant acute efficacy and durability of action demonstrated in three Phase 3 Trials • Early signals from 201 data and 303 study suggest t
Slide 27: Vazegepant: Third Generation CGRP Receptor Antagonist
FIRST INTRANASAL FORMULATION OF A SMALL MOLECULE CGRP RECEPTOR A NTAGONIST SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 27 • Superior chemical attributes • Potent antagonist at the human CGRP receptor • Highly soluble and high free fraction • US composition o
Slide 28: CGRP Platform Development Milestones & Next Steps
CGRP Platform Development Milestones & Next Steps SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 28 2Q19 Initiate a Phase 2 proof of concept trial to evaluate the safety and efficacy of rimegepant in patients with treatment refractory trigeminal neuralgia 2Q19
Slide 29: Rimegepant Commercial & Marketing Update
Rimegepant Commercial & Marketing Update
Slide 30: Commercial and Launch Readiness Remain on Timelines
SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 30 Biohaven’s Commercial and Launch Readiness Remain on Timelines Region Business Director (RBDs): COMPLETED hires District Business Manager (DBMs): Hires: 50% hire completed, on timelines Neuroscience and Primary
Slide 31: Biohaven's Experienced Commercial Leaders
Biohaven’s Experienced Commercial Leaders Mark Glackin • >30 yrs • Allergan/GSK Adrienne Ross • >30 yrs • BMS Jimi Ayodele • >25 yrs • PWC/Otsuka Chris Barrett • >25 yrs • Schering/BI/DBV Cassi O’Neil • >15 yrs • BMS/AZ/ITV HCP Marketing Chris Deluzio • >20 yrs • BMS/BI/AZ/Takeda Graham Goodrich • >
Slide 32: Managed Markets and National Accounts Team
SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 32 Biohaven Managed Markets and National Accounts Team K. Floeder, RPh • 25 years industry experience • 16 years account management Key Accounts • CVS • Aetna G. Tadlock, RPh • 25+ years industry experience • 13 ye
Slide 33: Highly Experienced Region Business Directors
33 Bernadette Raymond Industry: 30 yrs RBD: 15 yrs Biohaven’s Highly Experienced Region Business Directors (RBD) Lead National Commercial Sales Efforts Chris Deluzio SVP Sales/ Comm Ops BJ Jones CCO, Migraine & Common Diseases Chad McMahon Industry: 23 yrs RBD: 3 yrs Brian Keenan Industry: 20 yrs RB
Slide 34: Glutamate Platform
GLUTAMATE PLATFORM Therapies for Neurologic and Neuropsychiatric Indications
Slide 35: The Role of Glutamate in Brain Synapses
NORMAL FUNCTION Healthy State The Role of Glutamate: Present in 90% of Brain Synapses SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 35 EXCITOTOXICITY Diseased State AMYOTROPHIC LATERAL SCLEROSIS SPINOCEREBELLAR ATAXIA DEMENTIA NEURODEGENERATION NEUROTOXICITY S
Slide 36: Glutamate Mechanisms of Action in CNS
Glutamate Mechanisms of Action in CNS SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 36 Glutamate Transporter Modulation • Troriluzole • BHV - 0223 Glutamate NMDA Receptor Antagonism • BHV - 5000 Third - party clinical trials provide basis for exploration of ri
Slide 37: Unmet Medical Need in ALS
UNMET MEDICAL NEED IN ALS SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 37 Riluzole ( Rilutek ® ) is approved for the treatment of patients with amyotrophic lateral sclerosis (ALS) and proven to extend survival • Originally marketed by Sanofi, received FDA app
Slide 38: Troriluzole: Rational Drug Discovery to Optimize Therapy
Troriluzole: Rational Drug Discovery to Optimize Therapy SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 38 • Improved absorption • Enhanced bioavailability • Reduced drug burden • Reduced first pass metabolism • Favorable safety profile • Once - daily dosing
Slide 39: Peptide Transporter Enhances Absorption of Troriluzole
Peptide Transporter 1 Enhances Absorption of Troriluzole PepT1 PepT1 = Peptide Transporter 1 ACTIVE ABSORPTION IN INTESTINAL TRACT BY PEPT1 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 39
Slide 40: Troriluzole: Targeted Lead-Indication Development Strategy
Social Anxiety Disorder Generalized Anxiety Disorder Bipolar Depression Troriluzole: Targeted Lead - Indication Development Strategy SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 40 * = Third - party study / collaboration ongoing or planned (ADCS Collaboration
Slide 41: Troriluzole Phase 2/3 Trial Design: Generalized Anxiety Disorder
TRORILUZOLE (BHV - 4157) PHASE 2/3 TRIAL DESIGN GENERALIZED ANXIETY DISORDER • Chronic or excessive worry, restlessness, fatigue, difficulty concentrating, insomnia • Impairs ability to function socially or at work • Irritable bowel - like gastrointestinal issues • Significant unmet need • GAD has a
Slide 42: Yale POC Study: Anti-Anxiety Effects of BHV-0223
BHV - 0223 DESIGN • Double - blind, placebo controlled crossover trial with two Impromptu Speech Task sessions • Subjects diagnosed with Social Anxiety Disorder • N=22 randomized (21 completed) • BHV - 0223 vs PBO, dosed 1 hour prior to public speaking stress task; separated by two to ten days to al
Slide 43: Riluzole Preclinical Anti-Anxiety Effects
RILUZOLE PRECLINICAL Yale Human POC Study Is Consistent with Preclinical Models Showing Riluzole’s Anti - Anxiety Effects and Enhancement of Recognition Memory Sugiyama et al 2017 (Brain Behavioral Research) SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 43 Ant
Slide 44: Pathological Features of Alzheimer's Disease
Pathological Features of Alzheimer’s Disease • Brain atrophy • Neuronal cell death • Amyloid and tau pathology • Synapse loss (most highly correlated with clinical symptoms) • Glial cell dysfunction Congdon Nat Rev Neurol. 2018;14(7):399 - 415 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROL
Slide 45: Glutamate Transporter GLT-1 is Reduced in Human AD Brains
Glutamate Transporter (GLT - 1) is Reduced in Human AD Brains SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 45 Human autopsy observations from AD and controls (n=13) GLT - 1 immunoreactivity in temporal neocortex area in AD is significantly weaker than that in
Slide 46: Riluzole Rescues Symptoms, Function and Pathology in AD Models
Increases GLT - 1 Glutamate Transporter 4 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 46 Riluzole Rescues Symptoms, Function and Pathology in AD Animal Models 1 Pereira Proc Natl Acad Sci 2014; 2 Hunsberger J Neurochem 2015; 3 Hunsberger, Metab Brain Dis 201
Slide 47: Troriluzole Phase 2/3 Trial Design in Alzheimer's Disease
TRORILUZOLE (BHV - 4157) PHASE 2/3 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 47 • Key entry criteria • Diagnosis of mild to moderate Alzheimer’s disease with Mini - Mental State Exam (MMSE) score of 14 – 24 • Co - primary efficacy endpoints • Alzheimer's D
Slide 48: Cerebellar Ataxias
Cerebellar Ataxias SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 48 • Characterized by: • Poor balance with falls • Dysarthria / dysphagia • Incoordination of limbs • Cognitive impairment • Postural or kinetic tremor • Oculomotor dysfunction • Spinocerebellar
Slide 49: Troriluzole Treated SCA Patients vs Natural History Cohort
Troriluzole Treated SCA Patients Treated for 1 Year Compared to Matched Ashizawa Natural History Cohort SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 49 • Post - hoc analysis of patients enrolled in long - term extension of Phase 2b/3 troriluzole SCA trial • P
Slide 50: Study BHV4157-206: Randomized Trial of Troriluzole in SCA
Study BHV4157 - 206: Randomized Controlled Trial of Troriluzole in SCA Key Entry Criteria • SCA genotypes ( SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10) Design • Sample size: 230 subjects • Randomization: 1:1 • Stratification: by SCA genotype • Dose: Troriluzole 200 mg QD vs. Placebo QD • Primary Outc
Slide 51: Evidence for Glutamatergic Dysfunction in OCD
Accumulating Evidence for Glutamatergic Dysfunction in OCD SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 51 GENES ANIMAL MODELS NEURAL NETWORKS PATIENTS IN THE CLINIC Genetic association studies: Glutamate transporter gene (SLC1A1 on chromosome 9p24) associate
Slide 52: Neurochemical Evidence for Glutamate Dysregulation in OCD
Neurochemical Evidence for Glutamate Dysregulation in OCD SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 52 Rosenberg et al. 2000 Consistent with pathologic hyperactivity in cortico - striatal circuit Suggests clinical testing of agents that enhance glutamate u
Slide 53: Randomized Controlled Trial with Riluzole Augmentation
Randomized Controlled Trial with Riluzole Augmentation SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 53 • Outpatients with moderate to severe OCD severity (Y - BOCS score ≥ 21) and free of medication treatment for at least six weeks • Randomized to receive flu
Slide 54: Study BHV4157-202: Troriluzole in OCD
Study BHV4157 - 202: Randomized Controlled Trial of Troriluzole in OCD KEY ENTRY CRITERIA • Moderate to severe OCD and inadequate response to standard of care DESIGN • Sample size: 226 subjects • Randomization: 1:1 • Dose: Troriluzole 200 mg QD vs. Placebo QD (in patients on standard of care) • Prim
Slide 55: BHV-0223 Optimized to Address Riluzole Delivery Limitations for ALS
BHV - 0223 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 55 • Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that causes muscle weakness, difficulties with breathing and swallowing, and death • Generic riluzole has been proven t
Slide 56: BHV-0223 Phase 1 Single Dose PK Results
BHV - 0223 BHV - 0223 Phase 1 Single Dose PK Results SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 56 Observations • (A) Sublingual (SL) 35 mg dose of BHV - 0223 vs. 50 mg dose of oral Rilutek ( riluzole ) • (B) SL 40 mg BHV - 0223 vs. 50 mg Rilutek • BHV - 02
Slide 57: BHV-5000: A Novel Low-Trapping NMDA Antagonist
BHV - 5000 SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 57 • Potential first - in - class, next - generation NMDA receptor antagonist • Exclusive license from AstraZeneca • Low - trapping agent • Orally bioavailable prodrug of the IV drug lanicemine • NMDA mo
Slide 58: Glutamate Platform Development Milestones & Next Steps
Glutamate Platform Development Milestones & Next Steps SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 58 3Q2019 Complete Response Received, ongoing discussions with FDA for BHV - 0223 NDA for treatment of ALS via 505(b)(2) 4Q2019 Futility analysis expected in P
Slide 59: MPO Platform
MPO PLATFORM Therapies for Neuroinflammation
Slide 60: BHV-3241 for Neuroinflammation: Multiple System Atrophy
BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 60 • Rare, rapidly progressive and fatal neurodegenerative disease • Prevalence: 2 – 5 per 100,000 • Clinical symptoms • Parkinsonism: characteristic tremor (not responsive to L - D
Slide 61: BHV-3241 Background
BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 61 BHV - 3241 Background • Myeloperoxidase (MPO) enzyme • Key mediator of oxidative and inflammatory processes that lead to neurodegeneration • Promotes alpha - synuclein aggregatio
Slide 62: Neuroprotective Effects of BHV-3241 in MSA Animal Model
BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 62 Neuroprotective Effects of BHV - 3241 in MSA Animal Model 1 Reduces GCIs of alpha - synuclein Promotes functional (motor) improvements Suppresses microglial activation RLZ treate
Slide 63: BHV-3241 Clinical Experience
BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 63 • Studied in approximately 250 subjects (healthy volunteers, Parkinson’s disease, MSA) • Generally safe and well tolerated • Demonstrated target engagement ( ↓ blood MPO activity
Slide 64: Phase 2 Study in MSA Completed by AstraZeneca
BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 64 • Phase 2 study: randomized double - blind controlled trial • N=61 subjects (MSA - C, 34; MSA - P, 24) • Randomized to 12 weeks treatment • Placebo BID vs BHV - 3241 300 mg BID v
Slide 65: Plan for Phase 3 Study of BHV-3241 in MSA
BHV - 3241 FOR NEUROINFLAMMATION SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 65 DESIGN • Sample size: 252 subjects • Randomization: 1:1 • Dose: 600 mg BID vs. Placebo *based on Ph2 • Primary outcome measure: Unified MSA Rating Scale • Sites: US & EU (UK, FR,
Slide 66: MPO Platform Development Milestones & Next Steps
SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 66 MPO Platform Development Milestones & Next Steps Received Orphan Disease designation from FDA On track to Initiate a Phase 3 clinical trial for the treatment of MSA, a rare, rapidly progressive and fatal neuroin
Slide 67: Thank You!
Thank You! www.biohavenpharma.com Zydis ® is a registered trademark of Catalent. Rilutek ® is a registered trademark of Covis Pharma B.V. NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved.
Biohaven Pharmaceutical Holding — Investor Presentation (October 2019) on 6ix